1. Generics Bulletin
  2. >>Products
  3. >>Generics

Accord’s 12-Year-Old Prograf Generic Has US Equivalence Rating Pulled

FDA Funded Studies Reveal Increased Risk Of Toxicity For Accord’s Transplant Drug

 
• By Dean Rudge

Accord Healthcare has been told by the FDA that its generic version of Astellas Pharma’s Prograf capsules will no longer be automatically substituted for the brand following a series of post-approval studies dating back more than a decade.

FDASignBldg21Entrance_1200x675
• Source: Shutterstock

The US Food and Drug Administration has removed the AB-rating indicating therapeutic equivalence with the reference product for Accord Healthcare’s generic Prograf (tacrolimus) 0.5mg, 1mg, and 5mg capsules, after a series of post-approval studies raised concerns of the risk for increased toxicity for patients taking Accord’s generic compared to Astellas Pharma’s branded immunosuppressant.

Tacrolimus capsule and injectable dosage forms were approved by the FDA under the Prograf name in 1994. The first generic version of tacrolimus capsules, from Sandoz, was approved in August 2009, with many more following over the years

More from Generics

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Products